B. Braun Recalls Ceftazidime and Dextrose Injection Due to Stability Failures
B. Braun Medical Inc. is recalling one lot of Ceftazidime for Injection USP and Dextrose for Injection USP because the product failed stability specifications for high molecular weight polymers.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this as a Class I recall, which is the highest risk category indicating a reasonable probability that the product will cause serious adverse health consequences or death. The rubric states that FDA Class I recalls must be scored at least 4.
Plain-English summary
B. Braun Medical Inc., located in Bethlehem, PA, has initiated a voluntary recall of one lot of Ceftazidime for Injection USP and Dextrose for Injection USP, 2 g, 50 mL Duplex Container. The product is available by prescription only (RX only) and carries National Drug Code (NDC) 0264-3145-11.
The recall was triggered because testing revealed out-of-specification results for High Molecular Weight Polymers in the affected lots. This failure indicates that the product does not meet its established stability specifications.
The recalled product includes 22,488 duplex containers distributed nationwide within the United States. The specific lot subject to this recall is H8J812, with an expiration date of July 31, 2020.
Healthcare providers and patients should check their inventory for the identified lot number and expiration date. Any affected units should be returned or handled according to standard pharmaceutical recall procedures.
The recalled product
- Product
- Ceftazidime for Injection USP and Dextrose for Injection USP, 2 g, 50 mL Duplex Container, RX only, B Braun Medical Inc., Bethlehem, PA 18018-3524, NDC 0264-3145-11
- Manufacturer
- B. Braun Medical Inc
- Category
- Drug — Injection / Antibiotic
- Affected units
- 22,488
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: H8J812
- Exp. Date 31 JUL 2020
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · B. Braun Medical Inc
See all →- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- ModerateB. Braun UPMC double catheter trays contain Mastisol with cracking tubing
FDA (Devices) · 2026-06-10
- ModerateB. Braun Shands kits contain Mastisol adhesive with cracking tubing
FDA (Devices) · 2026-06-10
- ModerateB. Braun spinal epidural kits contain Mastisol with cracking tubing
FDA (Devices) · 2026-06-10
- ModerateB. Braun kits contain Mastisol adhesive with potentially cracking tubing
FDA (Devices) · 2026-06-10
Same hazard · stability failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateVasocaine lidocaine spray recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateCisatracurium 20 mg multiple-dose vials recalled after subpotent assay results
FDA (Drugs) · 2025-12-24